Previous meta-analyses of large cardiovascular outcome trials39,40 found that SGLT2 inhibitors have only modest effect on atherosclerotic major adverse cardiovascular outcomes in patients with type 2 diabetes mellitus, and this is confined to those with established atherosclerotic cardiovascular disease (ASCVD). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.